Mystic Asset Management Inc. Buys New Shares in Danaher Corporation $DHR

Mystic Asset Management Inc. acquired a new position in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,162 shares of the conglomerate’s stock, valued at approximately $4,467,000. Danaher makes up 1.0% of Mystic Asset Management Inc.’s portfolio, making the stock its 22nd biggest holding.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Danaher during the 2nd quarter valued at approximately $10,492,520,000. Jupiter Topco LLC acquired a new stake in Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the 2nd quarter valued at about $1,287,949,000. Bank of America Corp DE purchased a new position in Danaher during the 2nd quarter valued at about $993,846,000. Finally, Legal & General Group Plc purchased a new position in Danaher during the 2nd quarter valued at about $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DHR. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Royal Bank Of Canada increased their price target on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. UBS Group initiated coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Finally, Wells Fargo & Company cut their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Stock Up 3.0%

DHR opened at $231.52 on Friday. The business’s fifty day simple moving average is $213.55 and its 200 day simple moving average is $195.74. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a market cap of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the firm earned $0.77 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is currently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.